Ventyx Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch VTYX and buy or sell other stocks, ETFs, and their options commission-free!About VTYX
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
CEORaju S. Mohan, PhD
CEORaju S. Mohan, PhD
Employees—
Employees—
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2018
Founded2018
Employees—
Employees—
VTYX Key Statistics
Market cap998.72M
Market cap998.72M
Price-Earnings ratio-9.34
Price-Earnings ratio-9.34
Dividend yield—
Dividend yield—
Average volume732.43K
Average volume732.43K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$25.00
52 Week high$25.00
52 Week low$0.783
52 Week low$0.783
Stock Snapshot
With a market cap of 998.72M, Ventyx Biosciences(VTYX) trades at $14.00. The stock has a price-to-earnings ratio of -9.34.
On 2026-09-12, Ventyx Biosciences(VTYX) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 732.43K.
Over the past 52 weeks, Ventyx Biosciences(VTYX) stock has traded between a high of $25.00 and a low of $0.78.
Over the past 52 weeks, Ventyx Biosciences(VTYX) stock has traded between a high of $25.00 and a low of $0.78.
People also own
Based on the portfolios of people who own VTYX. This list is generated using Robinhood data, and it’s not a recommendation.